Molecule Details
| InChIKey | OLCWFLWEHWLBTO-HSZRJFAPSA-N |
|---|---|
| Compound Name | Bms-214662 |
| Canonical SMILES | N#Cc1ccc2c(c1)CN(S(=O)(=O)c1cccs1)[C@H](Cc1ccccc1)CN2Cc1c[nH]cn1 |
| Clinical Status | Clinical Multi-Target |
| Targets (Human+Pathogen) | 4 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.75 |
| Source | ChEMBL;BindingDB;TTD_MultiTarget |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12234 |
|---|---|
| Drug Name | BMS-214662 |
| CAS Number | 195987-41-8 |
| Groups | investigational |
| ATC Codes | nan |
| Description | BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, and Adult Acute Promyelocytic Leukemia (M3), among others. |
Categories: Benzazepines Heterocyclic Compounds, Fused-Ring
Cross-references: BindingDB: 50092365 CHEMBL351706 ChemSpider: 395310 PDB: BMV PubChem:448545 PubChem:347828513 ZINC: ZINC000003925649